IP Library › Granted Patent US 8,124,738
Granted Patent B2
US 8,124,738 · App. 12/065,436 · Granted Feb 28, 2012

Human monoclonal antibodies to CD70

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,124,738
App. No.
12/065,436
Granted
Feb 28, 2012
Kind
B2
Abstract

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for treating cancer, autoimmune disease, inflammation and viral infections.

Claims (75)

1. An isolated human monoclonal antibody or antigen binding portion thereof, wherein the antibody cross-competes for binding to CD70 with a reference antibody, or antigen binding portion thereof, wherein the reference antibody or reference antigen-binding portion thereof comprises:

(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:6;

(b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:7;

(c) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:8;

(d) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:9; or

(e) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:5 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:10.

2. An isolated monoclonal antibody, or antigen binding portion thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and light chain variable region are selected from the group consisting of:

(a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:1; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:6;

(b) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:2; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:7;

(c) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:3; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:8;

(d) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:4; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:9; and

(e) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:5; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:10;

wherein the antibody specifically binds to CD70.

3. The antibody, or antigen-binding portion thereof, of claim 2 , which comprises:

(a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:1; and

(b) a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:6.

4. An isolated monoclonal antibody or antigen binding portion thereof, which comprises:

a) a heavy chain variable region CDR1 comprising SEQ ID NO:11;

b) a heavy chain variable region CDR2 comprising SEQ ID NO:16;

c) a heavy chain variable region CDR3 comprising SEQ ID NO:21;

d) a light chain variable region CDR1 comprising SEQ ID NO:26;

e) a light chain variable region CDR2 comprising SEQ ID NO:31; and

f) a light chain variable region CDR3 comprising SEQ ID NO:36.

5. An isolated monoclonal antibody or antigen binding portion thereof, which comprises:

a) a heavy chain variable region CDR1 comprising SEQ ID NO:12;

b) a heavy chain variable region CDR2 comprising SEQ ID NO:17;

a heavy chain variable region CDR3 comprising SEQ ID NO:22;

c) a light chain variable region CDR1 comprising SEQ ID NO:27;

d) a light chain variable region CDR2 comprising SEQ ID NO:32; and

e) a light chain variable region CDR3 comprising SEQ ID NO:37.

6. An isolated monoclonal antibody or antigen binding portion thereof, which comprises:

a) a heavy chain variable region CDR1 comprising SEQ ID NO:13;

b) a heavy chain variable region CDR2 comprising SEQ ID NO:18;

c) a heavy chain variable region CDR3 comprising SEQ ID NO:23;

d) a light chain variable region CDR1 comprising SEQ ID NO:28;

e) a light chain variable region CDR2 comprising SEQ ID NO:33; and

f) a light chain variable region CDR3 comprising SEQ ID NO:38.

7. An isolated monoclonal antibody or antigen binding portion thereof, which comprises:

a) a heavy chain variable region CDR1 comprising SEQ ID NO:14;

b) a heavy chain variable region CDR2 comprising SEQ ID NO:19;

c) a heavy chain variable region CDR3 comprising SEQ ID NO:24;

d) a light chain variable region CDR1 comprising SEQ ID NO:29;

e) a light chain variable region CDR2 comprising SEQ ID NO:34; and

f) a light chain variable region CDR3 comprising SEQ ID NO:39.

8. An isolated monoclonal antibody, or antigen binding portion thereof, which comprises:

a) a heavy chain variable region CDR1 comprising SEQ ID NO:15;

b) a heavy chain variable region CDR2 comprising SEQ ID NO:20;

c) a heavy chain variable region CDR3 comprising SEQ ID NO:25;

d) a light chain variable region CDR1 comprising SEQ ID NO:30;

e) a light chain variable region CDR2 comprising SEQ ID NO:35; and

f) a light chain variable region CDR3 comprising SEQ ID NO:40.

9. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 1 , wherein the reference antibody comprises:

a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:5; and

b) a light chain variable region comprising the amino acid sequence of SEQ ID NO:10.

10. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 1 , wherein the reference antibody comprises:

a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:1; and

b) a light chain variable region comprising the amino acid sequence of SEQ ID NO:6.

11. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 1 , wherein the reference antibody comprises:

a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2; and

b) a light chain variable region comprising the amino acid sequence of SEQ ID NO:7.

12. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 1 , wherein the reference antibody comprises:

a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:3; and

b) a light chain variable region comprising the amino acid sequence of SEQ ID NO:8.

13. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 1 , wherein the reference antibody comprises:

a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4; and

b) a light chain variable region comprising the amino acid sequence of SEQ ID NO:9.

14. A composition comprising the antibody, or antigen-binding portion thereof, according to claim 1 , 2 , or 3 and a pharmaceutically acceptable carrier.

15. An immunoconjugate comprising the antibody, or antigen-binding portion thereof, according to claim 1 , 2 , or 3 , linked to a therapeutic agent.

16. The immunoconjugate of claim 15 , wherein the therapeutic agent is a cytotoxin.

17. The immunoconjugate of claim 15 , wherein the therapeutic agent is a radioactive isotope.

18. The antibody, or antigen binding portion thereof, of claim 1 , 2 or 3 , wherein said antibody is internalized.

19. The antibody, or antigen binding portion thereof, of claim 1 , 2 or 3 , wherein said antibody binds to a renal cell carcinoma tumor cell line selected from the group consisting of 786-O, A-498, ACHN, Caki-1 and Caki-2 cell lines.

20. The antibody, or antigen binding portion thereof, of claim 1 , 2 or 3 , wherein said antibody binds to a B-cell tumor cell line.

21. The antibody, or antigen binding portion thereof, of claim 20 , wherein the B-cell tumor cell line is selected from the group consisting of Daudi, HuT 78, Raji and Granta 519 cell lines.

22. The antibody, or antigen binding portion thereof, of claim 1 , 2 or 3 , wherein said antibody lacks fucose residues.

Assignments (3)
MERGER Recorded Mar 19, 2015
From: MEDAREX, L.L.C.
To: E. R. SQUIBB & SONS, L.L.C.
Reel/Frame 035226/0690 →
MERGER Recorded Jun 13, 2013
From: MEDAREX, INC.
To: MEDAREX, L.L.C.
Reel/Frame 030603/0924 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2008
From: TERRET, JONATHAN A.; LU, LI-SHENG; KING, DAVID J.; CARDARELLI, JOSEPHINE M.; PAN, CHIN; HUANG, HAICHUN; COCCIA, MARCO A.
To: MEDAREX, INC.
Reel/Frame 020979/0556 →